We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Precision BioSciences Inc | NASDAQ:DTIL | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.32 | -2.95% | 10.52 | 8.00 | 10.55 | 11.62 | 10.36 | 10.99 | 73,819 | 05:00:07 |
Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that the Company will participate in the Jefferies Cell & Genetic Medicine Summit taking place September 29-30, 2022.
Details for the company presentation are as follows: Date: Friday, September 30, 2022 Time: 2:00 PM ET Location: Lotte New York Palace Hotel
The presentation will be available via a recorded webcast accessible on Precision’s website in the Investors section under Events & Presentations: https://investor.precisionbiosciences.com/events-and-presentations. An archived replay will be available for approximately 30 days following the event.
About Precision BioSciences, Inc.
Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly precise and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Company’s pipeline consists of multiple ex vivo “off-the-shelf” CAR T immunotherapy clinical candidates and several in vivo gene editing candidates designed to cure genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences, please visit www.precisionbiosciences.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220922005120/en/
Investor Contact: Mei Burris Director, Investor Relations & Finance Mei.burris@precisionbiosciences.com
Media Contact: Maurissa Messier Senior Director, Corporate Communications Maurissa.Messier@precisionbiosciences.com
1 Year Precision BioSciences Chart |
1 Month Precision BioSciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions